Search results
Results From The WOW.Com Content Network
gemcitabine, cisplatin gemcitabine, dexamethasone, and cisplatin bladder cancer: GDP gemcitabine, dexamethasone, cisplatin: Non-Hodgkin lymphomas and Hodgkin lymphoma: GemOx or GEMOX: gemcitabine, oxaliplatin: Non-Hodgkin lymphomas: GVD: gemcitabine, vinorelbine, pegylated liposomal doxorubicin: Hodgkin lymphoma: GemOx-R or GEMOX-R or R-GemOx ...
Gemcitabine is a chemotherapy drug that works by killing any cells that are dividing. [11] Cancer cells divide rapidly and so are targeted at higher rates by gemcitabine, but many essential cells also divide rapidly, including cells in skin, the scalp, the stomach lining, and bone marrow, resulting in adverse effects. [17]: 265
Cisplatin is a chemical compound with formula cis-[Pt(NH 3) 2 Cl 2]. It is a coordination complex of platinum that is used as a chemotherapy medication used to treat a number of cancers . [ 3 ] These include testicular cancer , ovarian cancer , cervical cancer , bladder cancer , head and neck cancer , esophageal cancer , lung cancer ...
Cisplatin was the first to be developed. [9] Cisplatin is particularly effective against testicular cancer; the cure rate was improved from 10% to 85%. [10] Similarly, the addition of cisplatin to adjuvant chemotherapy led to a marked increase in disease-free survival rates for patients with medulloblastoma - again, up to around 85%.
Cisplatin and derivatives include cisplatin, carboplatin and oxaliplatin. [37] [38] They impair cell function by forming covalent bonds with the amino, carboxyl, sulfhydryl, and phosphate groups in biologically important molecules. [41] Non-classical alkylating agents include procarbazine and hexamethylmelamine. [37] [38]
Accepting the review's recommendations, the government advised that NHS hospitals should phase out the use of the LCP over the next 6–12 months, and that "NHS England should work with clinical commissioning groups (CCGs) to bring about an immediate end to local financial incentives for hospitals to promote a certain type of care for dying ...
Cisplatin, a platinum-based chemotherapeutic and radio sensitizer. A radiosensitizer is an agent that makes tumor cells more sensitive to radiation therapy. It is sometimes also known as a radiation sensitizer or radio-enhancer.
Most major toxicities of cisplatin, especially nephrotoxicity, were also reduced in the group of patients treated with lipoplatin and treatment did not require hospitalisation for lipoplatin patients. Median survival times were 10 months for the lipoplatin arm and 8 months for the cisplatin arm, with a ‘’p’’-value of 0.155.